< previous page | page_225 | next page >
Page 225
| Enzymes |
| Enzymes not only play a major role in digestion but also act as anti-inflammatory, fibrinolytic, and thrombolytic agents in the body. The use of enzymes in cancer therapy began in 1902 with John Beard, the leading embryologist of that time, whose book, The Enzyme Treatment of Cancer, became a classic. Since then the use of a wide range of enzyme preparations for the treatment of cancer has grown. |
| The main mechanism by which enzymes appear to inhibit cancer has to do with their fibrinolytic effects. Fibrinogen is four to fifteen times higher in cancerous tissue as compared to healthy tissue; the protective fibrin net that surrounds cancer cells helps to protect them from our own immune system. Enzyme preparations, taken in combination with specific herbs and mushroom extracts, work synergistically to break doom fibrin. Thus, many of my protocols combine enzymes with herbs and mushroom extracts; they should be taken together between meals to enhance their effectiveness. |
| Proteolytic Enzymes |
| Wobenzym |
| Proteolytic enzymes, such as trypsin, chymotrypsin, bromelain, papain, serratio-peptase, SOD (superoxide dismutase), amylase, protease, and lipase, all make up Wobenzym, called Wobe-Mucos in Germany where it is manufactured (see Resources). This oral preparation, which also comes in suppository form, is indicated for the treatment of many disorders, including pancreatic insufficiency, chronic pancreatitis, cystic fibrosis, multiple sclerosis, herpes zoster, and chronic inflammatory diseases. It is also used as an adjunct to radiation therapy and to inhibit mestastatic cancer. These enzymes are strong modulators of the immune system because they activate macrophages that induce phagocytosis and release tumor necrosis factor-alpha (TNF-alpha), TNF-beta, IL-1, and IL-2. They also activate cytotoxic lymphocytes and natural killer-cells. In addition, they cleave to certain immunologic-active proteins, which in turn stimulate lymphocytes to infiltrate tumor sites. |
| Circulating immune complexes (CIC) are known to be present in people with cancer and are responsible for much of the cancer-associated immunosuppression. Removal or modulation of these blocking factors can reverse this |
< previous page | page_225 | next page >

If you like this book, buy it!